Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
出版年份 2018 全文链接
标题
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
作者
关键词
-
出版物
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 115, Issue 43, Pages E10119-E10126
出版商
Proceedings of the National Academy of Sciences
发表日期
2018-10-09
DOI
10.1073/pnas.1802166115
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- High response rate to PD-1 blockade in desmoplastic melanomas
- (2018) Zeynep Eroglu et al. NATURE
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
- (2017) Vikram R. Juneja et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- MA 05.09 Pre-Existing Immunity Measured by Teff Gene Expression in Tumor Tissue is Associated with Atezolizumad Efficacy in NSCLC
- (2017) M. Kowanetz et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
- (2017) Elizabeth R Plimack et al. LANCET ONCOLOGY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
- (2017) Alice O. Kamphorst et al. SCIENCE
- Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
- (2017) Janet Lau et al. Nature Communications
- Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
- (2016) J. M. Kim et al. ANNALS OF ONCOLOGY
- The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
- (2016) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
- (2016) Lucia Festino et al. DRUGS
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- 15LBA High tumoral IFNγ mRNA, PD-L1 protein, and combined IFNγ mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients
- (2015) B.W. Higgs et al. EUROPEAN JOURNAL OF CANCER
- Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.
- (2015) Tanguy Y. Seiwert et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012.
- (2015) Kei Muro et al. JOURNAL OF CLINICAL ONCOLOGY
- A resource for cell line authentication, annotation and quality control
- (2015) Mamie Yu et al. NATURE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alterations of immune response of non-small cell lung cancer with Azacytidine
- (2015) John Wrangle et al. Oncotarget
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers
- (2014) Erica B. Schleifman et al. PLoS One
- Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
- (2014) Limo Chen et al. Nature Communications
- voom: precision weights unlock linear model analysis tools for RNA-seq read counts
- (2014) Charity W Law et al. GENOME BIOLOGY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- The evolving genomic classification of lung cancer
- (2013) David S Shames et al. JOURNAL OF PATHOLOGY
- DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non-Small Cell Lung Cancer
- (2012) K. Walter et al. CLINICAL CANCER RESEARCH
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search